









Markets
/
Stocks
/
nasdaq-rani
/

Rani Therapeutics Holdings Inc

RANI

2.380USD

+0.230+10.70%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

93.38MMarket Cap

LossP/E TTM



Rani Therapeutics Holdings Inc

2.380

+0.230+10.70%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Rani Therapeutics Holdings Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite strong stock market performance and technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Rani Therapeutics Holdings Inc's Score

Industry at a Glance

Industry Ranking

120 / 407

Overall Ranking

243 / 4617

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

10.500

Target Price

+377.27%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Rani Therapeutics Holdings Inc Highlights

StrengthsRisks

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. It has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-102, RT-105, RT-111 and RT-110. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200uL in liquid form with high bioavailability.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.03M.

Fairly Valued

The company’s latest PE is -2.37, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 8.06M shares, increasing 32.58% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 799.68K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.10.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 5.68, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.68

Change



Financials

5.38

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.23

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.06

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.13

Key Metrics

Free cash flow

No Data

Rani Therapeutics Holdings Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 8.76, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -2.37, which is -80.93% below the recent high of -0.45 and -157.23% above the recent low of -6.10.

Score

Industry at a Glance

Previous score

8.76

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 120/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Rani Therapeutics Holdings Inc is 10.50, with a high of 12.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

10.500

Target Price

+388.37%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Rani Therapeutics Holdings Inc

RANI

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 7.40, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 3.86 and the support level at 0.44, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.49

Change

-0.09

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(0)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.075

Buy

RSI(14)

66.579

Neutral

STOCH(KDJ)(9,3,3)

54.123

Buy

ATR(14)

0.721

High Vlolatility

CCI(14)

59.753

Neutral

Williams %R

43.716

Buy

TRIX(12,20)

6.060

Buy

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.968

Buy

MA10

1.983

Buy

MA20

1.496

Buy

MA50

0.898

Buy

MA100

0.714

Buy

MA200

0.951

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 8.26%, representing a quarter-over-quarter decrease of 70.54%. The largest institutional shareholder is The Vanguard, holding a total of 799.68K shares, representing 0.82% of shares outstanding, with 61.39% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Armistice Capital LLC

3.15M

South Lake One, LLC

8.30M

-31.57%

InCube Labs, L.L.C.

86.48K

Orca Capital GmbH

1.89M

The Vanguard Group, Inc.

Star Investors

799.68K

Nan Fung Life Sciences

493.58K

Imran (Talat)

306.10K

+7.78%

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 2.64, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.39. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.